SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| O'Connor Padraig Andrew | EVP, Global Operations | 2026-09-02 | Option exercise | 1171 | $0 |
| O'Connor Padraig Andrew | EVP, Global Operations | 2026-09-02 | Tax withholding | 567 | $27K |
| Morano Susan E | Director | 2026-08-25 | Open-market buy | 2040 | $100K |
| Woodworth Emily | SVP, Global Controller and CAO | 2026-08-11 | I | 2930 | $150K |
| Monson Jonathan | EVP and CFO | 2026-08-10 | I | 9908 | $500K |
| Habiger David C | Director | 2026-08-05 | Open-market buy | 2100 | $100K |
| Habiger David C | Director | 2026-08-04 | Open-market buy | 140 | $7K |
| Habiger David C | Director | 2026-08-03 | Open-market buy | 1042 | $50K |
| Mahoney Michael F | Chairman, President & CEO, Director | 2026-08-03 | Open-market buy | 186240 | $9.0M |
| Mahoney Michael F | Chairman, President & CEO, Director | 2026-08-03 | I | 22119 | $1.1M |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 2026-07-31 | I | 64198 | $3.0M |
| LUDWIG EDWARD J | Director | 2026-07-31 | Open-market buy | 5000 | $227K |
| Monson Jonathan | EVP and CFO | 2026-07-01 | Option exercise | 2087 | $0 |
| Monson Jonathan | EVP and CFO | 2026-07-01 | Tax withholding | 1010 | $43K |
| Mahoney Michael F | Chairman, President & CEO, Director | 2026-05-28 | Gift | 386755 | $0 |
| Habiger David C | Director | 2026-05-20 | Open-market buy | 2250 | $126K |
| LUDWIG EDWARD J | Director | 2026-05-20 | Open-market buy | 3580 | $203K |
| Pegus Cheryl | Director | 2026-05-20 | Open-market buy | 1770 | $100K |
| Habiger David C | Director | 2026-05-19 | Open-market buy | 2200 | $125K |
| Habiger David C | Director | 2026-05-07 | Grant/award | 3800 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Risk deteriorated broadly across regulatory, operational, and financial dimensions, with no meaningful offsets. The most consequential shifts are a 56% escalation in restructuring scope ($700-800M charges), a $690M debt increase to $11.4B, and a sharp expansion of regulatory exposure spanning tariffs, reimbursement conditionality, FCPA/SEC scrutiny, and China data-localization — all materializing simultaneously. Site-of-care migration and freight cost pressures add structural market and supply chain headwinds that compound the financial burden.
5 company-specific · 4 common-mode
Restructuring charges increased 56% ($450-550M to $700-800M) and expected savings increased 56% ($225-275M to $350-400M), signaling material escalation in program scope and financial impact.
We may not realize the expected benefits from our restructuring and optimization initiatives, our long-term cost savings programs may result in an increase in short-term expenses and our efforts may…
New disclosure of site-of-care migration risk (inpatient to outpatient/ASC/office-based) with impacts on reimbursement, pricing, and provider economics—a substantive market structural shift.
We may experience declines in market size, average selling prices for our products, medical procedure volumes and/or our share of the markets in which we compete, which could have an adverse effect…
Added substantive new reimbursement requirements: payers now demand health economic evidence, real-world outcomes, and post-market studies. Conditional coverage with potential withdrawal risk escalates operational and financial burden.
Health care cost containment pressures, government payment and delivery system reforms, changes in private payer policies, and marketplace consolidations could decrease the demand for our products…
Debt increased 6.4% ($690M) to $11.436B, worsening leverage risk. Added "approvals" language suggests regulatory delays now a concern.
Credit and Financial Risks If we are unable to manage our debt levels, maintain investment grade credit ratings at the three ratings agencies, or if we experience a disruption in our cash flows, it…
Added explicit mention of SEC inquiries, FCPA, export control, and trade embargo laws. Expands scope of regulatory scrutiny and investigation risk beyond prior healthcare-specific focus.
The medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations, often involving marketing and…
Tariff risk escalated from prospective Trump policy to actual implementation with ongoing Supreme Court litigation and potential refund uncertainty.
Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations…
International sales declined from 39% to 36% of global net sales. Risk language escalated: added "fines and penalties" and "reputational harm" to compliance consequences; shifted from conditional election language to "continues to exist significant uncertainty" on trade; expanded geopolitical conflict specificity (Taiwan strait explicitly named).
We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could adversely impact our business…
Added "increased freight costs" as a new supply chain risk. Reflects tangible cost pressure beyond prior disruption concerns.
Interruption of our supply chain or manufacturing operations, including resulting from natural disasters, public health crises, geopolitical developments or other events outside of our control, could…
Added explicit disclosure of China PIPL and data-localization requirements with compliance costs and operational complexity risks, escalating regulatory exposure.
We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse…
Boston Scientific discloses a material cybersecurity incident identified on August 25, 2026, involving unauthorized activity that caused a global network outage, disrupted manufacturing and order processing, and is "likely to have a material impact on the Company's results of operations for the third quarter and full year 2026," causing the company to withdraw prior guidance. The filing explicitly states the incident resulted in operational disruption and financial impact, meeting the definition of a material cybersecurity incident under Item 1.05.
View raw filing on EDGAR →Boston Scientific disclosed a cybersecurity incident detected on August 25, 2026, that has caused "global disruption to the Company's operations," including disruptions to order processing and shipping capabilities. The company explicitly states the incident has resulted in "disruptions and limitations of access to certain of the Company's information systems and business applications." While the company notes the full scope and financial impact are not yet determined, the operational disruption and involvement of third-party cybersecurity experts to contain the threat clearly constitute a material cybersecurity incident requiring disclosure under Item 1.05 (or Item 8.01 as here).
View raw filing on EDGAR →Boston Scientific issued a press release on July 29, 2026 announcing Q2 2026 financial results, including net sales of $5.442 billion (7.5% reported growth), GAAP net income of $0.61 per share, and adjusted EPS of $0.86 per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the earnings release furnished as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings announcements.
View raw filing on EDGAR →Boston Scientific's Board approved the "2026 Restructuring Plan" on July 21, 2026, which explicitly includes "headcount reductions" and "termination benefits" as part of a multi-year restructuring. The filing discloses estimated total pre-tax charges of $700–$800 million, with termination benefits of $275–$300 million, supply chain optimization, and functional transformation activities. This is a classic workforce reduction and operational restructuring event under Item 2.05, material to investors assessing the company's cost structure and future profitability.
View raw filing on EDGAR →